Ratings PolyPeptide Group AG

Equities

PPGN

CH1110760852

Real-time Estimate Cboe Europe Other stock markets 08:20:22 2024-05-23 am EDT			5-day change	1st Jan Change
33.35 ^CHF	+1.52%		+0.61%	+89.50%

Mar. 12	PolyPeptide Group AG Provides Earnings Guidance for 2024	CI
Mar. 12	Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024

Summary

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Its core activity has a significant growth potential and sales are expected to surge, according to Standard & Poor's' forecast. Indeed, those may increase by 50% by 2026.
Over the last twelve months, the sales forecast has been frequently revised upwards.
Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.
The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.

Weaknesses

The company has insufficient levels of profitability.
With an enterprise value anticipated at 3.31 times the sales for the current fiscal year, the company turns out to be overvalued.
The company appears highly valued given the size of its balance sheet.
The company is not the most generous with respect to shareholders' compensation.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last few months, analysts have been revising downwards their earnings forecast.
The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
The company's earnings releases usually do not meet expectations.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Pharmaceuticals

	1st Jan change	Capi.	ESG Refinitiv
POLYPEPTIDE GROUP AG	+89.50%	1.19B	B-
ELI LILLY AND COMPANY	+37.74%	723B	C+
NOVO NORDISK A/S	+34.39%	595B	B
JOHNSON & JOHNSON	-2.07%	369B	C+
MERCK & CO., INC.	+20.25%	332B	B-
ABBVIE INC.	+2.99%	282B	C+
ASTRAZENECA PLC	+17.04%	244B	B+
NOVARTIS AG	+9.80%	208B	B-
ROCHE HOLDING AG	-4.17%	205B	A+
PFIZER, INC.	+2.81%	168B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes